



News Release

Contact: Derma Sciences Inc
Edward J. Quilty
Chairman and CEO
equilty@dermasciences.com
(609) 514-4744

Allen & Caron Inc
Rudy Barrio (US Investors)
r.barrio@allencaron.com

Brian Kennedy (media)
brian@allencaron.com
(212) 691-8087

Skin & Aging Article Finds Derma Sciences MEDIHONEY™ Helps to Promote Healing Where Antibiotics Fail

Researchers Work in-vitro on MRSA, VRE and other multi-resistant organisms

PRINCETON, NJ – (May 2, 2008) . . . Derma Sciences (EBB: DSCI), a provider of advanced wound care products, today announced that the journal *Skin & Aging*, in its annual review of top wound care studies, devoted a section to MEDIHONEY™ Wound & Burn Dressings with Active *Leptospermum* Honey. The article, “Spotlighting the Top-10 Research Findings in Wound Care”, discusses the research done by Narelle George and Keith Cutting on the product’s *in-vitro* activity against clinical isolates of MRSA, VRE, and other multi-resistant gram-negative organisms including *Pseudomonas aeruginosa*.

The author of the article, Dr. Robert Kirsner, MD, PhD, and a past president of the Association for the Advancement of Wound Care, states, “A specific honey, the so-called Manuka honey predominantly sourced from the *Leptospermum* species from New Zealand and Australia, has been found to have other properties that may render it superior to other honeys. Specifically, this honey appears to have superior and broad-spectrum antimicrobial properties.” He went on to say that the first *Leptospermum* honey-based product to enter into the market, MEDIHONEY, is likely to draw significant interest from a public desirous of natural products, and that well-done studies such as the George/Cutting study will help to garner interest by medical professionals.

Derma Sciences CEO Ed Quilty stated, “We are fully aware that, although the benefits of MEDIHONEY have captured the imagination of the public and the medical community alike, it is only through well-designed studies and rigorous clinical evaluations with positive outcomes that widespread adoption and usage of MEDIHONEY will occur. We are glad to see the recognition of the George/Cutting study, and look forward to additional studies on MEDIHONEY being published later this year. Additionally, we continue to receive a stream of positive clinical evaluations from many wound centers around the globe.”

Quilty added, “Our next big milestone is the World Union of Wound Healing Societies conference in Toronto during the first week in June. This conference takes place only once every four years and it draws doctors interested in wound care from all over the globe.”

The *Skin & Aging* article also makes several additional key points:

- A retrospective study of 400 patients with wounds (pressure ulcers, diabetic ulcers, and venous ulcers) showed that wounds treated more frequently with antimicrobial dressings appeared less likely to heal rapidly, as did ulcers that were mechanically debrided.
- A randomized controlled study on healing rates of 71 non-healing venous leg ulcers showed that none of the patients receiving conservative care – defined as the use of hydrocolloid dressings under compression devices – saw the ulcers heal completely during the duration of the 6-month study period. Hydrocolloids are one of the most typical advanced wound care dressings utilized for first-line treatment of ulcers.

Both these points are notable with comparison to the recent Georgina Gethin study presented last Spring at the European Wound Management Association. This 108-patient randomized controlled study showed that 44% of the non-healing venous leg ulcers treated with Active *Leptospermum* Honey under compression devices healed within the 12-week study duration, in addition to lowering the incidence of infection. This underscores the wound healing benefit of the dressing in addition to its antimicrobial capability, a feature atypical within common antimicrobial dressings. The study also showed that the dressing was associated with improved autolytic debridement (a more natural and less invasive form of debridement than surgical/mechanical debridement).

To read the article, please go to: <http://www.skinandaging.com/article/8563>

(Information in this article concerns a use that has not been cleared by the US Food and Drug Administration.)

MORE-MORE-MORE

About Skin & Aging

Skin & Aging provides practical and clinical insight into today's general dermatology issues. This award-winning publication offers dermatologists reader-friendly, timely and informative articles that highlight clinical and practice management advice that easily can be translated into current practice settings.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand – the licensor of the patented honey-based technology – and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of two positive large-scale randomized controlled studies on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at www.dermasciences.com.

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.

#